PD Dr. rer. nat. Thomas Nerreter
Medizinische Klinik und Poliklinik II
Universitätsklinikum Würzburg
Versbacher Str. 5
97078 Würzburg
Phone: +49 931 201 71291
Email: Nerreter_T@ukw.de
University training and degree
2011 Diploma in Biology at the Goethe University Frankfurt am Main. Thesis supervisor: Prof. Dr. Jindrich Cinatl
2006 – 2011 Biology Studies at the Goethe University Frankfurt am Main
Advanced academic qualifications
2020-2022 Habilitation in ‘Experimental Medicine’, Julius Maximilian University Würzburg
2014 PhD graduation with the „Graduate School of Life Sciences“, Julius Maximilian University Würzburg, supervisor PD Dr. Ruth Seggewiß-Bernhardt
Postgraduate professional career
2014 – Postdoc and Senior Research Fellow position in the research Group ‘CAR T cell engineering’, Department of Medicine II, University Hospital Würzburg
2018 Wilsede Meeting, Travel Award
2018 Foundation FORSCHUNG HILFT, Research Award
a) Articles published by outlets with scientific quality assurance, book publications and works accepted for publication, but not yet published
1. Prommersberger S, Hudecek M, & Nerreter T. Antibody‐based CAR T cells produced by lentiviral transduction. Current Protocols in Immunology. 2020;128(1):e93. doi: 10.1002/cpim.93
2. Nerreter T*, Letschert S*, Götz R, Doose S, Danhof S, Einsele H, Sauer M, Hudecek M. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun. 2019; 10(1):3137.
3. Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019; 11:eaau5907.
4. Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M. Chimeric antigen receptor library screening using a novel NF-κB/NFAT reporter cell platform. Molecular Therapy. 2019;27(29):287-299.
5. Lohmeyer J*, Nerreter T*, Dotterweich J*, Einsele H, Seggewiss-Bernhardt R. Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose and time-dependent manner. Clin Exp Immunol. 2018;193(1):64-72. * shared first authorship.
6. Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M. CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168-1179.
7. Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez GJ, Fallahi M, Soden J, Freeth J, Beerli RR, Grawunder U, Hudecek M, Rader C. Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. J Mol Biol. 2017;429(19):2954-2973.
8. Nerreter T, Zeiß S, Herrmann T, Einsele H, Seggewiss-Bernhardt R. Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C+ CD57+ FcεRγ− NK cells in CMV seropositive human blood donors. Immunobiology 2017;222(5):719-725
9. Nerreter T, Köchel Ch, Jesper D, Eichelbrönner I, Putz E, Einsele H, Seggewiss-Bernhardt R. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Exp Hematol. 2014;42(9):773-82.e1-3.
10. Nerreter T, Distler E, Köchel Ca, Einsele H, Herr W, Seggewiss-Bernhardt R. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Exp Hematol. 2013;41(7):604-614.e4.